Drug
Sitravatinib clinical trials
Also written MGCD516 and BGB-9468.
- studies test it
- 31
- open now
- 1
- in phase 3
- 5
- first study started
- 2014
Keep track of what changes. Save the sitravatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2021 (8)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 8 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 17
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 14
Mirati Therapeutics Inc. (11) · BeiGene (5) · M.D. Anderson Cancer Center (2) · Seoul National University Hospital (1) · Zhejiang Cancer Hospital (1) · BeOne Medicines (1) · Grupo Español Multidisciplinar de Melanoma (1) · University of Birmingham (1)
Often tested with
Tested in the same studies.
Tislelizumab (11) · Nivolumab (7) · Docetaxel (2) · Pembrolizumab (2) · Pamiparib (1) · Hpk1 Inhibitor BGB-15025 (1) · Zanidatamab (1) · AZD4547 (1)
Studies
Open first, then newest update. How each study uses sitravatinib is read from its arms, and is right about nine times in ten.
Testing it · 31
- A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionRecruitingPhase 2Anhui Provincial HospitalNCT05407519Written as Tislelizumab + Sitravatinib
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedPhase 3Mirati Therapeutics Inc.NCT03906071Written as Sitravatinib
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedPhase 2/3Mirati Therapeutics Inc.NCT04887870Written as Sitravatinib
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedPhase 3BeOne MedicinesNCT04164199Written as Sitravatinib
- Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.CompletedPhase 2Grupo Español Multidisciplinar de MelanomaNCT05542342Written as Sitravatinib
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935Written as Sitravatinib
- Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedPhase 2M.D. Anderson Cancer CenterNCT04904302Written as Sitravatinib
- Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedPhase 3BeiGeneNCT04921358Written as Sitravatinib
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedPhase 2BeiGeneNCT05461794Written as Sitravatinib
- Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCTerminatedPhase 2Sarah GoldbergNCT04925986Written as Sitravatinib
- Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03015740Written as Sitravatinib
- A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedPhase 1BeiGeneNCT03666143Written as Sitravatinib
- Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy AdultsCompletedPhase 1BeiGeneNCT04472650Written as Sitravatinib
- Sitravatinib in Metastatic Breast CancerTerminatedPhase 2Xiang ZhangNCT04123704Written as Sitravatinib
- Sitravatinib in Advanced Liposarcoma and Other Soft Tissue SarcomasCompletedPhase 2Columbia UniversityNCT02978859Written as MGCD516
- Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedPhase 1Mirati Therapeutics Inc.NCT04518046Written as Sitravatinib
- PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.CompletedPhase 1Mirati Therapeutics Inc.NCT05255276Written as Sitravatinib 50 mg
- PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedPhase 1Mirati Therapeutics Inc.NCT04887194Written as Sitravatinib
- Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerTerminatedPhase 2Mirati Therapeutics Inc.NCT02954991Written as Sitravatinib
- Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract CancerActive, not recruitingPhase 2Seoul National University HospitalNCT04727996Written as Sitravatinib
See all 31 studies that test sitravatinib →
Given in every arm · 4 — sitravatinib is usual care beside what is tested
- A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingPhase 2Fudan UniversityNCT04734262Written as Sitravatinib
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedPhase 1/2BeiGeneNCT03941873Written as Sitravatinib
- A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaTerminatedPhase 2Mirati Therapeutics Inc.NCT03606174Written as Sitravatinib
- Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaStatus unknownPhase 2Peking University Cancer Hospital & InstituteNCT05104801Written as sitravatinib
Codes
What other systems call sitravatinib · ClinicalTrials.gg INT000552
- MeSH (NLM) C000611865sitravatinibOne source NLM
- UNII (FDA) CWG62Q1VTBSITRAVATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27275860sitravatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C117734SitravatinibOne source FDA
- DrugBank DB15036One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000611865 | sitravatinib | One source NLM |
| UNII (FDA) | CWG62Q1VTB | SITRAVATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27275860 | sitravatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C117734 | Sitravatinib | One source FDA |
| DrugBank | DB15036 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.